Tumors with increased GATA3 copy numbers were more often positive by GATA3 IHC (81.5%) than carcinomas with non-altered GATA3 copy number status (71.1%; p < 0.0001; Fig. 3A) and cancers with GATA3 high-level amplifications showed more often strong GATA3 immunostaining (42.1%) than carcinomas without high-level amplifications (29.9–31.8%; p = 0.0002, Fig. 3B) but 11.6% of cancers with high-level GATA3 amplification were GATA3 IHC negative. This evidence concerns the gene GATA3 and carcinoma.